Table 2.

Some clinical trials of TZDs for the treatment of different neurodegenerative diseases.

Agent	Disease	Outcome	Refs.
Rosiglitazone+Riluzole	ALS	Had no positive benefit	[50]
Rosiglitazone	AD	No improvement in ApoE ε4 allele carriers	[130]
Rosiglitazone	AD	No benefit in cognition or in global function in ApoE ε4 negative subjects	[67]
Pioglitazone	AD	Well tolerated but an increase in peripheral oedema	[63]
Glitazone	PD	A reduction in the incidence of PD in patients with diabetes	[18]
Pioglitazone	PD	Is unlikely to modify progression in early PD	[76]